Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized tacrolimus dosing in pediatric kidney transplant recipients
NL-OMON60730Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Jun 2024
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tacrolimus in kidney transplant immunosuppression (2 arms), sponsored by Erasmus MC. Primary endpoint: Percentage of children within tacrolimus target trough range on day 3. Started Jun 2024; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant immunosuppression
Beyond the preview
Go deeper on NL-OMON60730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60730.